BOULDER, Colo.--(BUSINESS WIRE)--Every year, nearly 7,200 infants are born in the United States with a Critical Congenital Heart Disease (CCHD). 1 It is a condition that is often easily detectable and ...

June 8, 2026 /3BL/ – Medtronic, a global leader in healthcare technology, announced FDA 510(k) clearance of its Nellcor™ pulse oximetry system with Nell-EQ™ intelligent processor. The Nell-EQ™ ...

OBJECTIVE: Pulse oximetry is a standard of care for monitoring oxygenation in neonates. Associated with the use of pulse oximetry is the cost of patient sensors, especially if the sensor is designed ...

DUBLIN, Feb. 9, 2021 /CNW/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the results of an independent, prospective observational study comparing the efficacy ...

Methods: Infants born via elective caesarean section were studied. ECG leads were placed on the infant's chest. Masimo and Nellcor oximeter sensors were randomly allocated to each foot. Measurements ...

International healthcare products major, Covidien plc (COV) has started labeling its Nellcor pulse oximeters to promote the usefulness of the product line for Critical Congenitial Heart Disease (:CCHD ...

Masimo is wagering $1 million that its pulse oximeters are more accurate than Covidien's.--Courtesy of Masimo Covidien ($COV) has racked up a few FDA clearances for ...

- Nellcor™ Pulse Oximetry Technology Demonstrated Statistically Significant Difference in Time to Deliver a Stable Oxygen Saturation Value and Heart Rate According to the study, a stable signal was ...

This regulatory milestone follows news from earlier this year, when the company announced positive verification study results for its Nellcor pulse oximetry system with Nell-EQ intelligent processor.